Single Dose Glumetinib in Healthy Chinese Male Subjects

Summary

This is a phase I, single-center, randomized, open-label, single-dose, three-period (fasting, high-fat meal, low-fat meal) crossover clinical study to investigate the food effect on PK of the recommended phase II dose (RP2D) of 300 mg Glumetinib, based on the previous clinical studies of Glumetinib monotherapy.

Timeline

Start

2021-03-02

Primary completion

2021-05-21

Completion

2021-09-30

Drugs

Indications

No indication recorded.